<SEC-DOCUMENT>0001104659-24-130954.txt : 20241220
<SEC-HEADER>0001104659-24-130954.hdr.sgml : 20241220
<ACCEPTANCE-DATETIME>20241220210014
ACCESSION NUMBER:		0001104659-24-130954
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20241220
DATE AS OF CHANGE:		20241220

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FATE THERAPEUTICS INC
		CENTRAL INDEX KEY:			0001434316
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				651311552
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-36076
		FILM NUMBER:		241569501

	BUSINESS ADDRESS:	
		STREET 1:		12278 SCRIPPS SUMMIT DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92131
		BUSINESS PHONE:		858.875.1803

	MAIL ADDRESS:	
		STREET 1:		12278 SCRIPPS SUMMIT DRIVE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92131

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Redmile Group, LLC
		CENTRAL INDEX KEY:			0001425738
		ORGANIZATION NAME:           	
		IRS NUMBER:				208592298
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		144

	BUSINESS ADDRESS:	
		STREET 1:		ONE LETTERMAN DRIVE
		STREET 2:		BUILDING D, SUITE D3-300
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94129
		BUSINESS PHONE:		415-489-9980

	MAIL ADDRESS:	
		STREET 1:		ONE LETTERMAN DRIVE
		STREET 2:		BUILDING D, SUITE D3-300
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94129
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>144</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: Redmile Group, LLC -->
          <cik>0001425738</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>


    </filerInfo>
  </headerData>
  <formData>
    <issuerInfo>
      <issuerCik>0001434316</issuerCik>
      <issuerName>FATE THERAPEUTICS INC</issuerName>
      <secFileNumber>001-36076</secFileNumber>
      <issuerAddress>
        <com:street1>12278 Scripps Summit Drive</com:street1>
        <com:city>San Diego</com:city>
        <com:stateOrCountry>CA</com:stateOrCountry>
        <com:zipCode>92131</com:zipCode>
      </issuerAddress>
      <issuerContactPhone>858-875-1800</issuerContactPhone>
      <nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Redmile Group, LLC</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
      <relationshipsToIssuer>
        <relationshipToIssuer>Director, 10% Stockholder</relationshipToIssuer>
      </relationshipsToIssuer>
    </issuerInfo>
    <securitiesInformation>
      <securitiesClassTitle>Common Stock, $0.001 par value(1)</securitiesClassTitle>
      <brokerOrMarketmakerDetails>
        <name>J.P. Morgan Securities LLC</name>
        <address>
          <com:street1>383 Madison Avenue</com:street1>
          <com:city>New York</com:city>
          <com:stateOrCountry>NY</com:stateOrCountry>
          <com:zipCode>10179</com:zipCode>
        </address>
      </brokerOrMarketmakerDetails>
      <noOfUnitsSold>341633</noOfUnitsSold>
      <aggregateMarketValue>567110.78</aggregateMarketValue>
      <noOfUnitsOutstanding>113894333</noOfUnitsOutstanding>
      <approxSaleDate>12/20/2024</approxSaleDate>
      <securitiesExchangeName>Nasdaq</securitiesExchangeName>
    </securitiesInformation>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock, $0.001 par value(1)</securitiesClassTitle>
      <acquiredDate>04/14/2023</acquiredDate>
      <natureOfAcquisitionTransaction>Private Placements from Stockholders</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Redmile Affiliates(2)</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>311523</amountOfSecuritiesAcquired>
      <paymentDate>04/14/2023</paymentDate>
      <natureOfPayment>Cash</natureOfPayment>
    </securitiesToBeSold>
    <securitiesToBeSold>
      <securitiesClassTitle>Common Stock, $0.001 par value(1)</securitiesClassTitle>
      <acquiredDate>04/14/2023</acquiredDate>
      <natureOfAcquisitionTransaction>Acquisition of Class A Convertible Preferred Stock in Private Placements from Stockholders and Subsequent Cashless Conversion to Common Stock on 12/12/2024</natureOfAcquisitionTransaction>
      <nameOfPersonfromWhomAcquired>Class A Convertible Preferred Stock from Redmile Affiliates(2); Common Stock from Issuer</nameOfPersonfromWhomAcquired>
      <isGiftTransaction>N</isGiftTransaction>
      <amountOfSecuritiesAcquired>30110</amountOfSecuritiesAcquired>
      <paymentDate>04/14/2023</paymentDate>
      <natureOfPayment>Purchase of Class A Convertible Preferred Stock for Cash; Cashless Conversion to Common Stock</natureOfPayment>
    </securitiesToBeSold>
    <nothingToReportFlagOnSecuritiesSoldInPast3Months>Y</nothingToReportFlagOnSecuritiesSoldInPast3Months>
    <remarks>(1) The total number of shares of Common Stock that may be sold represents shares that may be sold on an aggregate basis by private investment vehicles managed by Redmile Group, LLC, as follows: Redmile Strategic Trading Sub, Ltd. - 35,528 shares; and Redmile Strategic Long Only Trading Sub, Ltd. - 306,105 shares. (2) "Redmile Affiliates" means certain private investment funds and sub-advised accounts for which Redmile Group, LLC serves as an investment manager/adviser. (3) Redmile Group, LLC is the investment manager of Redmile Strategic Trading Sub, Ltd. and Redmile Strategic Long Only Trading Sub, Ltd.</remarks>
    <noticeSignature>
      <noticeDate>12/20/2024</noticeDate>
      <signature>/s/ Joshua Garcia, Chief Financial Officer, Redmile Group, LLC(3)</signature>
    </noticeSignature>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
